Evidence map›Paper›PMID 34385244›Full record

ArticleBMJ open2021

Involvement of people who inject drugs in injection initiation events: a cross-sectional analysis identifying similarities and differences across three North American settings.

Charles Marks, Stephanie A Meyers, Sonia Jain, Xiaoying Sun, Kanna Hayashi, Patricia Gonzalez-Zuniga, Steffanie A Strathdee, Richard S Garfein, M J Milloy, Kora DeBeck and 2 more

Abstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Charles MarksDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Stephanie A MeyersDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Sonia JainBiostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA.
Xiaoying SunBiostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA.
Kanna HayashiHealth Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Patricia Gonzalez-ZunigaDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Steffanie A StrathdeeDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Richard S GarfeinFamily Medicine and Public Health, University of California San Diego, La Jolla, California, USA.
M J MilloyBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Kora DeBeckBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Kevin CumminsDepartment of Public Health, CSU Fullerton, Fullerton, California, USA.
Dan WerbDepartment of Medicine, University of California San Diego, La Jolla, California, USA dwerb@health.ucsd.edu.ORCID 0000-0003-0614-9386

Funding

Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDSU01DA038886 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI DEBECK, KORA, HAYASHI, KANNA · 2015 to 2024
$12.1M
Impact of Drug Policy Reform on the HIV Risk Environment among IDUs in TijuanaR37DA019829 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2010 to 2019
$6.7M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersU01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2017 to 2024
$4.3M
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUsR01DA031074 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARFEIN, RICHARD S · 2011 to 2015
$3.2M
Preventing HIV by modifying the context for injecting initiationDP2DA040256 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WERB, DANIEL M · 2015 to 2015
$2.3M
CIHRNIDA NIH HHS DP2 DA040256NIDA NIH HHS R01 DA031074NIDA NIH HHS R37 DA019829NIDA NIH HHS U01 DA021525NIDA NIH HHS U01 DA038886
6 · The paper itself

Abstract

objectivesPeople who inject drugs (PWID) play an integral role in facilitating the entry of others into injection drug use (IDU). We sought to assess factors influencing PWID in providing IDU initiation assistance across three distinct North American settings and to generate pooled measures of risk.

designWe employed data from three PWID cohort studies participating in

settingTijuana, Mexico; San Diego, USA; Vancouver, Canada.

participantsA total of 2944 participants were included in this study (Tijuana: n=766, San Diego: n=353, Vancouver: n=1825). MEASUREMENTS: The outcome was defined as recently (ie, past 6 months) assisting in an IDU initiation event. Independent variables of interest were identified from previous PRIMER analyses. Site-specific multiple modified Poisson regressions were fit. Pooled relative risks (pRR) were calculated and heterogeneity across sites was assessed via linear random effects models.

resultsEvidence across all three sites indicated that having a history of providing IDU initiation assistance (pRR: 4.83, 95% CI: 3.49 to 6.66) and recently being stopped by law enforcement (pRR: 1.49, 95% CI: 1.07 to 2.07) were associated with a higher risk of providing assistance with IDU initiation; while recent opioid agonist treatment (OAT) enrolment (pRR: 0.64, 95% CI: 0.43 to 0.96) and no recent IDU (pRR: 0.21, 95% CI: 0.07 to 0.64) were associated with a lower risk. We identified substantial differences across site in the association of age (I

conclusionWe identified common and site-specific factors related to PWID's risk of assisting in IDU initiation events. Individuals reporting a history of assisting IDU initiations, being recently stopped by law enforcement, and recently injecting methamphetamine/speedball were more likely to have recently assisted an IDU initiation. Whereas those who reported not recently engaging in IDU and those recently enrolled in OAT were less likely to have done so. Interventions and harm reduction strategies aimed at reducing the harms of IDU should incorporate context-specific approaches to reduce the initiation of IDU.

Indexed as

Pharmaceutical PreparationsSubstance Abuse, IntravenousCohort StudiesCross-Sectional StudiesHumansMexicoPharmaceutical Preparationsepidemiologypublic healthstatistics & research methodssubstance misuse

Identifiers

PMID34385244
PMCPMC8362731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.